Standard antifungal therapy in neutropenic patients

International Journal of Antimicrobial Agents

Volumn 16, Issue 2, 2000, Pages 143-145

  Aoun, M ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Amphotericin B; Fungal infections; Prolonged neutropenia

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLOSIS; DRUG EFFICACY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; HUMAN; MYCOSIS; NEPHROTOXICITY; PRIORITY JOURNAL; SIDE EFFECT;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; FEVER; FLUCYTOSINE; HUMAN; MYCOSES; NEUTROPENIA;

EID: 0033780556     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(00)00220-X     Document Type: Article

References (8)

1. Reducing amphotericin B reactions. A double blind study
2. Risk factors for amphotericin B-associated nephrotoxicity
3. Amphotericin B serum concentrations during therapy
4. Distribution and activity of amphotericin B in humans
5. The structure and functional amphotericin B-cholesterol pores in lipid bilayer membranes
6. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia
7. Bone marrow toxicity associated with flourocytosine therapy
8. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients with neutropenia